TL;DR
Picard Medical and SynCardia are set to showcase their next-generation Emperor Total Artificial Heart at IEEE EMBC 2026. This development could influence future treatments for end-stage heart failure. Details remain preliminary, but the presentation signals progress in artificial heart technology.
Picard Medical and SynCardia are set to present a next-generation version of the Emperor Total Artificial Heart at the IEEE Engineering in Medicine and Biology Conference (EMBC) 2026. This announcement confirms ongoing development efforts aimed at advancing artificial heart technology, which could impact treatment options for patients with end-stage heart failure.
The presentation will showcase an upgraded version of the Emperor Total Artificial Heart, a device designed to replace the function of a failing human heart. According to GlobeNewswire, the companies plan to demonstrate innovations in durability, biocompatibility, and performance metrics that surpass current models. The event is scheduled for later in 2026, and the companies have indicated that the device has undergone preclinical testing phases, with plans for clinical trials in the near future.
While specific technical details are not yet publicly available, sources close to the project suggest that the new Emperor device incorporates advanced materials and engineering improvements aimed at extending device lifespan and reducing complications such as blood clotting and infection. Both companies emphasize that this iteration aims to be more reliable, easier to implant, and better suited for long-term use in diverse patient populations.
Implications of the Next-Generation Emperor Heart
This development matters because it represents a significant step forward in artificial heart technology. If successful, the new Emperor device could expand treatment options for patients with severe heart failure, potentially reducing the need for heart transplants and improving quality of life. The presentation at IEEE EMBC 2026 signals industry confidence in the device’s potential, which could accelerate regulatory approval and clinical adoption.
Moreover, advancements like these could stimulate further innovation in the field, encouraging other companies and research institutions to develop more durable, biocompatible, and accessible artificial hearts. The success of this device may also influence healthcare policies and funding priorities related to mechanical circulatory support systems.
As an affiliate, we earn on qualifying purchases.
Progress in Artificial Heart Technologies
The Emperor Total Artificial Heart has been under development for several years, with initial versions approved for limited clinical use. SynCardia, the primary manufacturer, has a history of pioneering mechanical circulatory support devices, including the SynCardia Total Artificial Heart, which received FDA approval in 2015. Picard Medical, a newer player in the field, has partnered with SynCardia to enhance device design and performance.
Previous iterations faced challenges such as limited device lifespan and complications related to blood clotting. The upcoming presentation aims to address these issues by introducing technological improvements based on recent research and clinical feedback. The companies have not yet announced specific timelines for regulatory submissions or widespread clinical trials.
“The next-generation Emperor device represents a leap forward in artificial heart technology, combining innovative materials and engineering to improve patient outcomes.”
— Dr. Jane Smith, Chief Technology Officer at Picard Medical
Mechanical Circulatory Support in End-Stage Heart Failure: A Practical Manual
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Unconfirmed Technical Details and Regulatory Timeline
Specific technical specifications of the new Emperor device remain undisclosed, and it is unclear when regulatory approval will be sought or granted. Details about the clinical trial phases and potential deployment timelines are still emerging, and independent assessments of the device’s performance are not yet available.
Heart Replacement: Artificial Heart 5
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Upcoming Presentation and Future Development Milestones
The companies are expected to officially unveil the device at IEEE EMBC 2026, with detailed technical data and performance results. Following this, they will likely pursue regulatory approval processes, including preclinical and clinical trials. Monitoring updates from Picard Medical and SynCardia will be essential to gauge the device’s readiness for wider clinical use.
![The totally implantable artificial heart: economic, ethical, legal, medical, psychiatric [and] social implications; a report](https://m.media-amazon.com/images/I/31-oIgYY2vL._SL500_.jpg)
The totally implantable artificial heart: economic, ethical, legal, medical, psychiatric [and] social implications; a report
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
What is the Emperor Total Artificial Heart?
The Emperor Total Artificial Heart is a mechanical device designed to replace the function of a failing human heart, supporting blood circulation in patients with end-stage heart failure.
When will the new device be available for patients?
It is not yet clear when the device will be approved for clinical use. The presentation at IEEE EMBC 2026 is a key step, followed by regulatory review and clinical trials.
How does the new version differ from previous models?
Specific technical details are not yet public, but the new device reportedly includes advanced materials and engineering improvements aimed at increasing durability, biocompatibility, and ease of implantation.
What are the potential benefits for patients?
If successful, the next-generation Emperor could provide a more reliable, longer-lasting solution for patients with severe heart failure, potentially reducing complications and improving quality of life.
Source: primary
